Biography

After starting his organic chemistry studies at the University of Montpellier-France , Cyril B. DOUSSON obtained his master of chemistry and bio-organic chemistry from the University of Marseille, then obtained his Ph.D. in 2000 from the University of Liverpool-UK under the supervision of Pr. Stanley M. Roberts, working on chiral bicyclic phosphorylated ligands for organometallic asymmetric catalysis in collaboration with Chirotech Technologies.
He joined AstraZeneca oncology medicinal chemistry group in Alderley Park-UK, and worked on the discovery of Barasertib a highly selective Aurora B kinase inhibitor.
In 2003, Cyril B. DOUSSON joined Idenix pharmaceuticals in Montpellier-France, and headed the medicinal chemistry department and site from 2012 to 2017.
In 2014, he was appointed Site head and medicinal chemistry department head of Merck & Co. Montpellier site.
In 2018, Cyril Dousson co-Founded Ai-biopharma, a start-up biotech company engaged in Artificial Intelligence-aided drug discovery for human health.
During the last 20 years, he participated in and led several drug discovery programs which have advanced in clinical trials against, amongst other, hepatitis C virus and other antiviral programs such as IDX375 (HCV polymerase inhibitor), Samatasvir (HCV-NS5A inhibitor) and MK-3682 (Nucleotide-prodrug HCV polymerase inhibitor), Fosdevirine (HIV NNRTI)…
Cyril B. DOUSSON is co-inventor and -author of over 60 publications, patents and patent applications.
https://www.linkedin.com/in/cbdousson
https://www.researchgate.net/profile/Cyril_Dousson